[1] Iqbal K， Alonso-Adel C， El-Akkad E， et al. Pharmacological targets to inhibit Alzheimer neurofibrillary degeneration [J]. J Neural Transm， 2002， (62) ：309. [2] Lau LF， Schachter JB， Seymour PA， et al. Tau protein phosphorylation as a therapeutic target in Alzheimer's disease[J］. Curr Top Med Chem， 2002 ，2(4) ：395. [3] Hamdane M， Smet C， Sambo AV， et al. Pin1： a therapeutic target in Alzheimer neurodegeneration [J]. J Mol Neurosci ，2002 ，19(3) ：275. [4] Lau LF， Seymour PA， Sanner MA， et al. Cdk5 as a drug target for the treatment of Alzheimer's disease [J]. J Mol Neurosci， 2002 ，19(3) ：267. [5] Tsai JY， Wolfe MS， Xia W. The search for gamma-secretase and development of inhibitors [J]. Curr Med Chem， 2002，9(11) ：1087. [6] Vassar R. Beta-Secretase (BACE) as a drug target for Alzheimer's disease [J]. Adv Drug Deliv Rev， 2002 ，54(12) ：1589. [7] Adessi C， Frossard MJ， Boissard C， et al. Pharmacological profiles of peptide drug candidates for the treatment of Alzheimer's disease [J]. J Biol Chem，2003 ，278(16) ：13905. [8] Matsuoka Y， Saito M， LaFrancois J， et al. Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid [J]. J Neurosci， 2003 ，23(1) ：29. [9] Pasinetti GM. Cyclooxygenase as a target for the antiamyloidogenic activities of nonsteroidal anti-inflammatory drugs in Alzheimer's disease [J]. Neurosignals， 2002 ，11(5) ：293. [10]Lee HG， Zhu X， Ghanbari HA，et al. Differential regulation of glutamate receptors in Alzheimer's disease [J]. Neurosignals， 2002 ，11(5) ：282. [11]Zeng L， Lu L， Muller M， et al. Structure-based functional design of chemical ligands for AMPA-subtype glutamate receptors [J]. J Mol Neurosci， 2002 ，19(1～2) ：113. [12]Klein RC， Castellino FJ. Activators and inhibitors of the ion channel of the NMDA receptor [J]. Curr Drug Targets， 2001 ，2(3) ：323. [13]Bleich S， Romer K， Wiltfang J， et al. Glutamate and the glutamate receptor system： a target for drug action [J]. Int J Geriatr Psychiatry，2003，18(Suppl 1) ：33. [14]Parra D， Gonzalez A， Mugueta C， et al. Laboratory approach to mitochondrial diseases [J]. J Physiol Biochem，2001 ，57(3) ：267. [15]Maximov V， Martynenko A， Hunsmann G， et al. Mitochondrial 16S rRNA gene encodes a functional peptide， a potential drug for Alzheimer's disease and target for cancer therapy [J]. Med Hypotheses， 2002 ，59(6) ：670. [16]Tatebayashi Y， Lee MH， Li L， et al. The dentate gyrus neurogenesis： a therapeutic target for Alzheimer's disease [J]. Acta Neuropathol(Berl)， 2003 ，105(3) ： 225. [17]Windisch M， Hutter-Paier B， Schreiner E. Current drugs and future hopes in the treatment of Alzheimer's disease [J]. J Neural Transm， 2002 ，(62) ：149. [18]Fillion G. Potential of 5-HT-moduline as a drug target for affective disorders [J]. Curr Opin Investig Drugs， 2000 ，1(1) ：104. [19]Joyce JN. Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs [J]. Pharmacol Ther， 2001 ，90(2～3) ：231. [20]Oak JN， Oldenhof J， van Tol HH. The dopamine D(4) receptor： one decade of research [J]. Eur J Pharmacol， 2000 ，405(1～3) ：303. [21]Quik M， Polonskaya Y， Kulak JM， et al. Vulnerability of 125I-alpha-conotoxin MII binding sites to nigrostriatal damage in monkey [J]. J Neurosci， 2001 ，21(15) ：5494. [22]Ikeda K， Kurokawa M， Aoyama S， et al. Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease [J]. J Neurochem， 2002 ，80(2) ：262. [23]Przedborski S， Chen Q， Vila M， et al. Oxidative post-translational modifications of alpha-synuclein in the 1-methyl-4-phenyl-1，2，3，6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease [J]. J Neurochem， 2001，76(2) ：637. [24]Araki T， Muramatsu Y， Tanaka K， et al. Riluzole (2-amino6-trifluoro-methoxybenzothiazole) attenuates MPTP (1-methyl-4-phenyl-1，2，3，6-tetrahydropyridine) neurotoxicity in mice [J]. Neurosci Lett， 2001 ，312(1) ：50. [25]Burke WJ. 3，4-dihydroxyphenylacetaldehyde： a potential target for neuroprotective therapy in Parkinson's disease [J]. Curr Drug Target CNS Neurol Disord， 2003 ，2 (2) ：143. [26]Valerio A， Ferrario M， Paterlini M， et al. Spinal cord mGlu1a receptors： possible target for amyotrophic lateral sclerosis therapy [J]. Pharmacol Biochem Behav， 2002 ，73(2) ：447. [27]Fournier AE， GrandPre T， Strittmatter SM. Identification of a receptor mediating Nogo-66 inhibition of axonal regeneration[J]. Nature， 2001 ，409(6818) ：341.